Natera (NASDAQ:NTRA) Price Target Raised to $230.00

Natera (NASDAQ:NTRA) had its target price raised by Barclays from $210.00 to $230.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the medical research company’s stock.

A number of other research analysts also recently commented on the stock. Stephens reaffirmed an “overweight” rating and set a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. Piper Sandler restated an “overweight” rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Evercore ISI lifted their price target on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday. Cowen reissued a “buy” rating on shares of Natera in a research report on Friday, August 8th. Finally, BNP Paribas Exane raised shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target on the stock in a research report on Monday, October 27th. Seventeen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $206.74.

Natera Stock Up 3.5%

NASDAQ NTRA traded up $7.06 on Friday, hitting $206.63. 1,452,469 shares of the stock were exchanged, compared to its average volume of 1,426,470. The company has a 50-day moving average price of $177.75 and a 200-day moving average price of $163.91. The company has a market cap of $28.36 billion, a PE ratio of -90.23 and a beta of 1.74. Natera has a fifty-two week low of $125.38 and a fifty-two week high of $210.90.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, November 6th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.20%. The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same period in the previous year, the firm earned ($0.26) earnings per share. The business’s revenue was up 34.7% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Natera will post -1.49 EPS for the current fiscal year.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 1,867 shares of the stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $190.64, for a total value of $355,924.88. Following the completion of the sale, the chief financial officer directly owned 64,126 shares of the company’s stock, valued at approximately $12,224,980.64. This represents a 2.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00. Following the sale, the insider owned 112,061 shares of the company’s stock, valued at approximately $22,255,314.60. This represents a 2.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 224,889 shares of company stock valued at $43,232,062 in the last 90 days. Company insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

Institutional investors have recently modified their holdings of the company. Axxcess Wealth Management LLC lifted its position in shares of Natera by 119.1% during the 1st quarter. Axxcess Wealth Management LLC now owns 3,122 shares of the medical research company’s stock worth $441,000 after purchasing an additional 1,697 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Natera by 36.2% during the first quarter. Nisa Investment Advisors LLC now owns 32,142 shares of the medical research company’s stock worth $4,545,000 after buying an additional 8,542 shares during the last quarter. Bridges Investment Management Inc. lifted its holdings in shares of Natera by 5.5% during the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company’s stock worth $237,000 after buying an additional 87 shares during the last quarter. Cerity Partners LLC boosted its position in shares of Natera by 7.3% in the first quarter. Cerity Partners LLC now owns 85,645 shares of the medical research company’s stock valued at $12,111,000 after acquiring an additional 5,863 shares during the period. Finally, Xponance Inc. boosted its position in shares of Natera by 41.3% in the first quarter. Xponance Inc. now owns 22,562 shares of the medical research company’s stock valued at $3,190,000 after acquiring an additional 6,591 shares during the period. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.